Under Settlement With Medicis, Lupin Gets License to Sell Solodyn Generic in November

Indian drugmaker Lupin Ltd. July 25 said it ended patent infringement litigation with Medicis Pharmaceutical Corp. over Lupin’s abbreviated new drug application to make generic versions of the acne treatment Solodyn (minocycline HCI) extended release tablets (Medicis Pharmaceutical Corp. v. Lupin Ltd.).

Under the parties’ settlement agreement, Lupin will receive a license from Medicis to sell its generic versions of Solodyn in 45 mg, 90 mg, and 135 mg strengths starting in November, or earlier under certain circumstances.

In addition, under the settlement, Lupin will receive a license from Medicis to sell its 65 mg and 115 mg ...